Quarterly ResultAug 6, 2026, 05:01 PM
Sanuwave Q2 Revenue Down 3% to $9.7M; Withdraws 2026 Guidance
AI Summary
Sanuwave Health reported Q2 2026 revenues of $9.7 million, a 3% decrease year-over-year, and a GAAP operating loss of $(0.3) million, down from $1.4 million income in Q2 2025. The company also posted a net loss of $0.7 million and a decline in Adjusted EBITDA to $1.2 million. Despite a challenging market, Ultramist applicator revenue increased by 13%, though system sales were negatively impacted by CMS reimbursement changes and a growing market for used systems. Due to ongoing market uncertainty and proposed CMS reimbursement changes for 2027, Sanuwave has withdrawn its previously issued fiscal year 2026 guidance.
Key Highlights
- Q2 2026 revenue was $9.7 million, down 3% from $10.1 million in Q2 2025.
- Q2 2026 gross margin was 76.2%, down from 78.1% in Q2 2025.
- GAAP Operating Loss was $(0.3) million in Q2 2026, compared to $1.4 million income in Q2 2025.
- Net loss for Q2 2026 was $0.7 million, versus net income of $0.6 million in Q2 2025.
- Adjusted EBITDA for Q2 2026 was $1.2 million, down from $3.2 million in Q2 2025.
- Ultramist applicator revenue increased 13% to $7.3 million in Q2 2026.
- 82 Ultramist systems were sold in Q2 2026, down from 116 in Q2 2025.
- Sanuwave withdrew its fiscal year 2026 guidance due to market conditions and CMS reimbursement developments.
Price Impact
More from SNWV